Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology for Alzheimer’s Disease

Cambridge, MA, March 22, 2023 (Business Wire) -- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. New investors Alzheimer’s Drug Discovery Foundation (ADDF), Starbloom Capital, IAG Capital and WS Investment Company (Wilson Sonsini’s venture arm) joined the round. The Series B funding brings the total amount raised since inception to $93 million.

Read full article here.